UPDATE: Bank of America Reinstates Coverage on Seattle Genetics as High Expectations are Priced In

In a report published Monday, Bank of America analyst Steve Byrne reinstated coverage on Seattle Genetics (NASDAQ: SGEN ) with an Underperform rating and $46.00 price target. In the report, Bank of America noted, “We are reinstating SGEN coverage with an Underperform rating and $46 PO. We believe the current